10-Q: Evoke Pharma Q2 Sales Surge Amid Going Concern Doubts

Evoke Pharma reported significant revenue growth for its Gimoti nasal spray in the second quarter of 2025, yet continues to face substantial doubt regarding its ability to continue as a going concern.

Summary

• Evoke Pharma, Inc. reported net product sales of $3,752,142 for the three months ended June 30, 2025, a 47% increase from $2,551,366 in the same period of 2024.
• For the six months ended June 30, 2025, net product sales reached $6,832,300, up 59% from $4,286,856 in the prior year.
• The company incurred a net loss of $(1,570,976) for the three months ended June 30, 2025, compared to a net loss of $(1,267,218) for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $(2,877,154), slightly higher than $(2,847,038) in 2024.
• Cash and cash equivalents stood at $12,059,072 as of June 30, 2025, down from $13,596,600 at December 31, 2024.
• The company has a $5.0 million note payable to Eversana, with accrued interest of $2,361,610, totaling $7.36 million as of June 30, 2025, which could become due within 90 days if Eversana exercises its termination right.
• New inbound prescriptions for Gimoti increased by 9.3% to approximately 1,960 in Q2 2025 compared to Q1 2025.
• The refill rate for patients with additional refills on their prescription was approximately 70%.
• New prescribers increased by 9.0% during Q2 2025.
• The company regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on June 4, 2024, and the Minimum Bid Price Requirement on August 15, 2024, following a 1-for-12 reverse stock split effective August 1, 2024.

Sentiment

Score: 3

Explanation: While the company shows strong sales growth for its sole product, Gimoti, and positive clinical data, the persistent 'going concern' doubt, increasing net losses, and significant liquidity risk from the Eversana loan overshadow these positives. The need for future capital raises and the potential for the Eversana loan to be called back within 90 days indicate a precarious financial position despite revenue improvements.

Positives

• Significant increase in net product sales for Gimoti, up 47% in Q2 2025 and 59% in H1 2025 compared to the prior year periods.
• Improved patient capture and conversion to reimbursed fills due to expanded pharmacy network and increased patient communication via ASPN Pharmacy.
• Growth in new inbound prescriptions (9.3% increase in Q2 2025) and new prescribers (9.0% increase in Q2 2025).
• High refill rate of approximately 70% for patients with additional refills.
• Real-world evidence studies indicate Gimoti leads to significantly fewer physician office visits, emergency department visits (60% reduction), and inpatient hospitalizations (68% reduction) compared to oral metoclopramide, resulting in approximately $15,000 in patient and payor cost savings over six months.
• Data suggests a far lower incidence of tardive dyskinesia (0.12%) for metoclopramide in gastroparesis patients than previously published.
• Regained compliance with Nasdaq listing requirements (Minimum Stockholders Equity and Minimum Bid Price).
• Net cash used in operating activities decreased from $(3,400,005) in H1 2024 to $(1,562,527) in H1 2025.

Negatives

• Incurred recurring net losses since inception, with net loss increasing in Q2 2025 compared to Q2 2024.
• Substantial doubt about the company's ability to continue as a going concern for one year from the financial statement issuance date.
• Cash and cash equivalents decreased to $12.1 million as of June 30, 2025, from $13.6 million at December 31, 2024.
• The $7.4 million principal and accrued interest on the Eversana loan could become due within 90 days if Eversana exercises its Net Profit Quarterly Termination Right, which was triggered as of June 30, 2025.
• If the Eversana agreement terminates, the company would need to establish its own substantial commercial infrastructure.
• Selling, general and administrative expenses increased significantly by $1.4 million (38%) in Q2 2025 and $2.6 million (37%) in H1 2025, primarily due to increased marketing and Eversana profit sharing.
• Research and development expenses increased significantly (1002% for six months ended June 30, 2025) due to miscellaneous product development costs.
• The One Big Beautiful Bill Act (OBBBA) enacted in July 2025 imposes significant reductions in Medicaid funding, which could adversely affect Gimoti sales.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses, negative cash flows, and the potential acceleration of the $7.4 million Eversana loan.
• Dependence on the commercial success of Gimoti; failure to grow sales could adversely affect financial position.
• Risk of Eversana terminating the commercial services and loan agreement if net profit remains negative for two consecutive quarters, which would require immediate repayment of the $7.4 million loan and establishing a new commercial infrastructure.
• Inability to secure adequate additional funding when needed or on acceptable terms, potentially forcing spending reductions, extended payment terms, or curtailment of commercialization activities.
• Potential for a complete loss of investment if unable to secure additional financing or execute strategic alternatives, leading to liquidation or winding down operations.
• Uncertainty and potentially significant costs associated with the FDA post-marketing commitment single-dose PK clinical trial for a lower dose strength of Gimoti.
• Future legislative and regulatory changes in healthcare, including the Inflation Reduction Act of 2022 (IRA) and the One Big Beautiful Bill Act (OBBBA), could increase commercialization costs, affect pricing, reduce demand, or put pressure on product pricing, particularly through Medicare price negotiations and Medicaid funding reductions.
• Competition with well-established products, including oral and intravenous forms of metoclopramide.
• Ability to manufacture sufficient quantities of Gimoti and reliance on contract manufacturers and suppliers.
• Costs associated with maintaining, expanding, and protecting intellectual property rights.

Future Outlook

The company anticipates continued operating losses due to commercialization activities, including manufacturing Gimoti and conducting a post-marketing commitment single-dose pharmacokinetics (PK) clinical trial for a lower dose strength of Gimoti. Existing cash and cash equivalents are expected to fund operations into the third quarter of 2026, but this excludes the potential early repayment of the $7.4 million Eversana Credit Facility. The company expects to be required to raise additional funds to continue as a going concern and may pursue additional clinical trials to expand Gimoti's indication. Future net sales of Gimoti are expected to offset commercialization activities, keeping cash used in operating activities in line with prior periods.

Management Comments

• Management believes that there is substantial doubt about the Company's ability to continue as a going concern for one year after the date these financial statements are issued.
• We have no intent to terminate the Eversana Agreement.
• We believe, based on our current operating plan, excluding any potential early repayment of the Eversana Credit Facility, that our existing cash and cash equivalents as of June 30, 2025, as well as cash flows from future net sales of Gimoti, will be sufficient to fund our operations into the third quarter of 2026.
• We expect that cash used in operating activities during the remainder of 2025 will be in-line with cash used during similar periods in 2024 because growing sales are expected to offset commercialization activities, including manufacturing Gimoti.

Industry Context

Evoke Pharma operates in the specialty pharmaceutical sector, specifically targeting gastrointestinal disorders with its sole product, Gimoti, for diabetic gastroparesis. The company's focus on a niche market with a unique nasal administration method positions it against established oral and intravenous metoclopramide products. The broader industry faces increasing legislative and regulatory pressures, including drug pricing reforms (e.g., IRA, OBBBA) and efforts to encourage generic competition, which could impact profitability and market access. The company's real-world evidence studies highlighting reduced healthcare utilization and cost savings for Gimoti users align with industry trends emphasizing value-based care and cost-effectiveness.

Comparison to Industry Standards

• Gimoti's real-world evidence showed a 60% reduction in physician office and emergency room visits and a 68% reduction in inpatient admissions compared to oral metoclopramide, leading to $15,000 in savings over six months. This demonstrates a significant improvement in patient outcomes and cost-efficiency compared to the standard oral treatment for gastroparesis.
• The reported 0.12% incidence of tardive dyskinesia (TD) for gastroparesis patients taking any form of metoclopramide from a U.S. database covering over 270 million patient lives is presented as 'far lower' than previously published, suggesting a potentially better safety profile than general perceptions of metoclopramide.
• The company's reliance on a single commercial product (Gimoti) and a commercial partner (Eversana) is common for smaller pharmaceutical companies but also presents a concentrated business risk compared to diversified larger pharmaceutical firms.

Management Changes

Corporate Governance

Related Party Transactions

• Eversana Life Science Services, LLC: Commercial partner for Gimoti, also provided a $5.0 million revolving credit facility. The company records sales for Gimoti and reimburses Eversana for commercialization costs and a percentage of product profits. Unreimbursed commercialization costs to Eversana were approximately $79.8 million as of June 30, 2025.
• Nantahala Capital Management, LLC: Entered into a letter agreement on September 27, 2024, granting Nantahala the right to appoint board members based on their beneficial ownership of common stock (one member for >=5.0%, two for >=15.0%).

Stakeholder Impact

• Shareholders: Face substantial doubt about the company's going concern ability and potential dilution from future capital raises. The reverse stock split aimed to maintain Nasdaq listing, which benefits shareholders by ensuring liquidity. The potential acceleration of the Eversana loan poses a significant risk to shareholder value.
• Employees: Continued operations are dependent on securing additional funding and the success of Gimoti. Potential curtailment of activities if funding is not secured could impact employment.
• Customers (Patients): Continued access to Gimoti depends on the company's ability to maintain commercialization activities, either through Eversana or by establishing its own infrastructure. Positive real-world data on Gimoti's effectiveness and cost savings benefits patients.
• Suppliers/Creditors: The going concern doubt and potential for the Eversana loan to be called back could raise concerns about the company's ability to meet contractual obligations.
• Eversana: As a commercial partner and creditor, Eversana's financial interests are tied to Gimoti's profitability and the company's financial stability. The NPQTR provides Eversana with a mechanism to terminate the agreement and demand loan repayment if profitability targets are not met.

Next Steps

• Conduct the FDA post-marketing commitment single-dose PK clinical trial of Gimoti to characterize dose proportionality of a lower dose strength.
• Potentially pursue additional clinical trials to expand the indication of Gimoti.
• Continue commercialization activities for Gimoti, including manufacturing.
• Maintain, expand, and protect the intellectual property portfolio.
• Raise additional funds through debt, equity, or collaboration arrangements to support future operations.
• Continue expanding the dispensing pharmacy network on the ASPN platform.

Key Dates

Recommendation

Despite strong sales growth for Gimoti and positive clinical data, the company faces severe financial distress, explicitly stating 'substantial doubt about its ability to continue as a going concern.' The $7.4 million loan from Eversana is callable within 90 days due to negative net profits, which would exhaust current cash reserves and necessitate a significant, immediate capital raise or the establishment of a costly new commercial infrastructure. The recurring losses and reliance on a single product amplify the risk. While past capital raises have provided temporary relief, the fundamental financial instability and the explicit going concern warning make the stock a high-risk investment with significant downside potential, warranting a sell recommendation for risk-averse investors.

Keywords

Evoke Pharma, Gimoti, Diabetic Gastroparesis, Pharmaceutical, Specialty Pharma, SEC Filing, 10-Q, Financial Results, Biotech, Drug Commercialization, Metoclopramide, Nasal Spray, Eversana, Going Concern, Nasdaq Listing, Healthcare Policy, Drug Pricing, Clinical Trials